Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715588 | 0.98 | TSHR (0.44) | L3MBTL1MEN1KMT2ATDP1TSHR | |
| SCHEMBL6722997 | 0.98 | TSHR (0.42) | L3MBTL1MEN1KMT2ATDP1TSHR | |
| SCHEMBL6716649 | 0.95 | TSHR (0.46) | L3MBTL1MEN1KMT2ATDP1TSHR | |
| SCHEMBL2094342 | 0.93 | L3MBTL1 (0.41) | L3MBTL1MEN1KMT2ATDP1TSHR | |
| SCHEMBL21055025 | 0.91 | TSHR (0.46) | TSHRFAAHTRPV1 | |
| SCHEMBL4630231 | 0.91 | TSHR (0.42) | L3MBTL1MEN1KMT2ATDP1TSHR | |
| SCHEMBL21925314 | 0.86 | TSHR (0.44) | TSHRFAAHTRPV1 | |
| SCHEMBL1448087 | 0.83 | ALDH1A1 (0.35) | L3MBTL1MEN1KMT2ATDP1TSHR | |
| SCHEMBL1447629 | 0.83 | ALDH1A1 (0.35) | L3MBTL1MEN1KMT2ATDP1TSHR | |
| SCHEMBL378009 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1323726-A1 | ERYTHROMYCIN DERIVATIVES AND MEDICINES CONTAINING THE SAME | HOKURIKU SEIYAKU CO., LTD. (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-5488140-A | ANTICONVULSANTS | CIBA-GEIGY CORPORATION (US) | 1996-01-30 | — | — | US | disclosed |
| EP-0420806-B1 | Phosphonic acids, process for preparation and use as an active pharmaceutical composition | CIBA GEIGY AG (CH) | 1995-07-05 | — | — | EP | disclosed |
| US-5294734-A | 1-phosphato-4-amino-pent-2-enoic acids and derivatives | CIBA-GEIGY CORP. (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0420806-A1 | Phosphonic acids, process for preparation and use as an active pharmaceutical composition | CIBA-GEIGY AG (CH) | 1991-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127433-A1 | excellent antibacterial activity especially against a typical acid-fast mycobacteria including multiple drug-resistant bacteria | MAPRE1, MAPRE2, MRPS27 | L3MBTL1 1807/4885MEN1 4240/4885KMT2A 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.